{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"110"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.","groups":[{"description":"Brigatinib 90 mg, tablets, orally, once daily in each Cycle of 28 days until disease progression or intolerable toxicity (median duration of exposure was 402 days).","id":"OG000","title":"Brigatinib 90 mg"},{"description":"Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in Cycle 2 and onward Cycles of 28 days until disease progression or intolerable toxicity (median duration of exposure was 522 days).","id":"OG001","title":"Brigatinib 90 mg - 180 mg"}],"paramType":"NUMBER","populationDescription":"Safety Population included all participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug up to 30 days following the last dose of study drug (approximately up to 69 months)","title":"Number of Participants Who Had at Least One Treatment-Emergent Adverse Event (TEAE)","type":"SECONDARY","unitOfMeasure":"participants"}